Valeant Pharmaceuticals to acquire OraPharma
The total acquistion value is considered to be $312m and around $114m based on certain pre-determined milestones which also includes revenue targets. As of 31March 2012, US-based OraPharma’s
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
Under the agreement Clarity’s PET based companion diagnostics and radio-immunotherapeutics development program will receive cGMP chemistry manufacturing,scale up and aseptic fill/finish services and analytical support from Dalton Pharma.